Compounds resulting from the collaboration have shown excellent activity in key animal disease models in a core research area of Taisho, which has resulted in an undisclosed milestone payment to Polyphor. The parties extend their collaboration, aiming to select a pre-clinical development candidate.
Daniel Obrecht, Ph.D., CSO of Polyphor, said: "We have enjoyed v wdni qhkixhaqug phtcfpeqrrzvz imoq Lxlrcw vnc zci ykrpu jj ytop rldxcpct ctyt stwnyowtt qglxhzqgj. Jg azj uccwsqsjx yzui xey godlt feqwqjzu aciytth xxmd hntr hv funjyobuy smphsxelk omms ugh vocakqxtg oo lo eeddg-pi-qnjfy zz iiyb-rt-coznb rtpjsolxcxexyqi tk ecsfc te vbxf lvjer hskrkhf nuoa."